Fertinex Side Effects
Generic Name: urofollitropin
Please note - some side effects for Fertinex may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects of Fertinex - for the Consumer
Fertinex
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Fertinex:
Seek medical attention right away if any of these SEVERE side effects occur when using Fertinex:Breast tenderness; headache; hot flashes; nausea; stomach pain; vaginal bleeding.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloating; chills; continuing diarrhea; fever; infrequent urination; nausea; pain or redness at the injection site; severe headache; severe pelvic pain; severe stomach pain or swelling; shortness of breath; swelling of the lower legs; vomiting; weakness; weight gain.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
TopSide Effects by Body System - for Healthcare Professionals
Cardiovascular
Cardiovascular side effects have include venous thrombophlebitis, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb. In rare cases, thromboembolic events have resulted in death.
Dermatologic
Dermatologic side effects have included dry skin, body rash, hair loss, and hives.
Gastrointestinal
Gastrointestinal side effects have included nausea, vomiting, diarrhea, abdominal cramps, and bloating.
General
General side effects have included headache and abdominal pain.
Genitourinary
Mild to moderate uncomplicated ovarian enlargement has been reported to generally regress without treatment within two or three weeks.
Severe OHSS may progress over one to several days to become a serious medical event. Severe OHSS is characterized by an apparent dramatic increase in vascular permeability which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially the pericardium. Early warning signs include severe pelvic pain, nausea, vomiting, and weight gain. Cases of OHSS may include abdominal pain, abdominal distension, nausea, vomiting, diarrhea, severe ovarian enlargement, weight gain, dyspnea, and oliguria. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events. Transient liver function test abnormalities have also been associated with OHSS.
Genitourinary side effects have included mild to moderate ovarian enlargement sometimes accompanied by abdominal distention and/or abdominal pain (20%), severe ovarian hyperstimulation syndrome (OHSS)(6%), breast tenderness, and ovarian cysts.
Local
Local side effects have included pain, rash, swelling, and/or irritation at the site of injection.
Oncologic
Oncologic side effects have included infrequent reports of neoplasms (both benign and malignant) in women who have undergone multiple drug regimens for ovulation induction. However, a causal relationship has not been established.
Other
Other side effects have included reactions including chills, musculoskeletal aches, joint pains, malaise, headache, and fatigue.
It is not clear whether the febrile reactions were pyrogenic responses or possible allergic reactions.
Respiratory
Respiratory side effects have included atelectasis, pulmonary embolism, pulmonary infarction, and acute respiratory distress syndrome. In rare cases, pulmonary complications have resulted in death.
TopMore Fertinex resources
- Fertinex MedFacts Consumer Leaflet (Wolters Kluwer)
- Fertinex Advanced Consumer (Micromedex) - Includes Dosage Information
- Urofollitropin Professional Patient Advice (Wolters Kluwer)
- Bravelle Prescribing Information (FDA)
- Bravelle Concise Consumer Information (Cerner Multum)
- Bravelle MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
